Agios Pharmaceuticals Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Net Revenue: $44.7 million, with $40.9 million from the U.S. and $3.8 million internationally.

Cost of Sales: $3 million.

Research and Development Expense: $100.8 million, up from $91.9 million in Q2 2025, primarily due to a $25 million upfront payment related to the cevidoplenib agreement.

Selling, General and Administrative Expense: $51.5 million, compared to $45.9 million in the prior year, reflecting increased commercial activities.

Net Loss: $100.7 million, an improvement from a net loss of $112 million in Q2 2025.

Cash Position: Approximately $1 billion in cash, cash equivalents, and marketable securities.

2Strategic Updates and Business Highlights

AQVESME Launch: Continued strong commercial performance with 442 cumulative prescriptions. The launch is progressing well, with a focus on expanding into the non-transfusion-dependent thalassemia population.

Mitapivat Expansion: Received FDA acceptance for a supplemental New Drug Application (sNDA) for sickle cell disease with a PDUFA goal date of November 1, 2026.

Pipeline Development: In-licensed cevidoplenib, a selective oral SYK inhibitor for immune thrombocytopenia, and advanced AG-236 into a Phase II/III program for polycythemia vera.

Clinical Data: Positive data presented at EHA regarding Mitapivat’s efficacy in both thalassemia and sickle cell disease, supporting its potential in the market.

3Forward Guidance and Outlook

Revenue Expectations: Anticipate $45 million to $50 million from pyruvate kinase deficiency in the U.S. for the full year.

Operating Expenses: Expected to remain flat compared to 2025, excluding the one-time payment for cevidoplenib.

Focus Areas: Continued emphasis on driving AQVESME’s launch, preparing for the potential sickle cell disease approval, and advancing the pipeline while maintaining financial discipline.

4Bad News, Challenges, or Points of Concern

Market Dynamics: Transitioning from highly motivated transfusion-dependent patients to a broader non-transfusion-dependent population may lead to variability in new patient starts and revenue growth.

Time to Treatment Initiation: As the patient mix shifts, the time to treatment initiation may extend to the anticipated 10- to 12-week range, which could impact revenue timing.

Competitive Pressures: The potential for a higher Medicaid mix in sickle cell disease could lead to increased gross-to-net dynamics, affecting net revenue per patient.

5Notable Q&A Insights

Patient Persistence: High continuation rates observed in clinical trials (over 90% in open-label extensions) may not fully translate to real-world scenarios as the patient population diversifies.

Launch Dynamics: The initial surge in prescriptions may not be sustainable as the company moves deeper into the non-transfusion-dependent segment, which has less frequent healthcare interactions.

Regulatory and Pricing Strategy: The company is prepared to launch Mitapivat for sickle cell disease with or without a Risk Evaluation and Mitigation Strategy (REMS), and pricing will be influenced by competitive dynamics and the final label.

Future Metrics: The company plans to shift focus from prescription counts to revenue as the primary measure of commercial performance after Q3 2026, reflecting a more comprehensive view of business health. Overall, Agios Pharmaceuticals demonstrated strong commercial momentum and pipeline advancement in Q2 2026, while navigating challenges associated with market dynamics and patient treatment patterns.